TIA Flashcards
In the new definition of TIA, one of the following is NOT TRUE:
a) Transient episode of neurological dysfunction caused by focal brain or retinal ischemia
b) Transient episode of neurological dysfunction caused by spinal cord ischemia
c) No evidence of acute infarct in the imaging
d) Symptoms last for less than 24 hours
d) Symptoms last for less than 24 hours (LESS THAN ONE HOUR; ssp 6th p 12)
It is indicated to hospitalize a TIA patient if he presents with ONE of the following:
a) The symptoms presented within 5 days.
b) The patient has an ABCD2 score of 3 (
c) The patient is 65 yo with BP of 150/100 and CBG of 210
d) The patient has chronic AF
It is indicated to hospitalize a TIA patient if he presents with ONE of the following:
a) The symptoms presented within 5 days. (SHOULD BE WITHIN 48 HRS)
b) The patient has an ABCD2 score of 3 (ADMISSION IS UNECESSARY FOR A SCORE OF 0-3)
√c) The patient is 65 yo with BP of 150/100 and CBG of 210 (SCORE OF 4; ssp table 8)
d) The patient has chronic AF (SHOULD BE CHRONIC AF)
One of the following is least likely to be a differential diagnosis of TIA.
a) Migraine with aura
b) Progressive memory decline
c) Focal seizure
d) Psychosomatic disorders
b) Progressive memory decline (ssp p 19)
True of amaurosis fugax:
a) It is a transient blindness of both eyes
b) It is mostly due to embolism from the vertebral artery
c) It is warranted to do plain ct scan of the brain
d) It is considered as a TIA
a) It is a transient blindness of both eyes (TRANSIENT MONOCULAR BLINDNESS)
b) It is mostly due to embolism from the vertebral artery (ICA)
c) It is warranted to do plain ct scan of the brain (ALMOST ALWAYS NORMAL)
√d) It is considered as a TIA
The risk of stoke 3 months after a TIA is:
a) 10%
b) 30%
c) 50%
d) 90%
a) 10% (10-15%; harrisons)
In the prevention of stroke from a TIA, one of the following is correct:
a) Lowering BP to levels BELOW those traditionally defining HPN reduce the risk of stroke even further
b) In the SPARCL trial, use of atorvastatin 80 mg showed benefit in the primary stroke prevention.
c) In the JUPITER trial, the use of Rosuvastatin decreases stroke by 51% as a secondary stroke prevention
d) High dose ASA is the most widely used antiplatelet as it reversively inhibits the formation in platelets of thromboxane A2.
a) Lowering BP to levels BELOW those traditionally defining HPN reduce the risk of stroke even further (harrisons)
Match the antiplatelet, Aspirin, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
a) Thromboxane A2 inhibitor
Match the antiplatelet, Clopidogrel, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
Match the antiplatelet, Ticlopidine, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
c) Blocks ADP receptor on platelets
Match the antiplatelet, Dypiridamole, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
b) Inhibits uptake of adenosine
Match the antiplatelet, Sulodexide, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
e) Heparanase 1 inhibitor
Match the antiplatelet, Cilostazol, with the mechanism of action in the prevention of stroke from a TIA:
a) Thromboxane A2 inhibitor
b) Inhibits uptake of adenosine
c) Blocks ADP receptor on platelets
d) Selective inhibitor of PDE3
e) Heparanase 1 inhibitor
f) Inhibits binding of ADP to platelet P2Y12 Receptor
d) Selective inhibitor of PDE3
One of the following is NOT TRUE:
a) The risk of stroke after an amaurosis fugax is higher than a cerebral TIA from a carotid atherosclerotic disease.
b) The occurrence of carotid TIA is a predictor not only of cerebral infarction but also of myocardial infarction.
c) About 2/3 of all patients with TIA are males with HPN.
d) A single TIA which is longer than one hour and multiple episodes of TIAs of different patterns suggest embolism.
a) The risk of stroke after an amaurosis fugax is higher than a cerebral TIA from a carotid atherosclerotic disease. (LOWER; adams)
